Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1

Clinical Infectious Diseases

Volumn 42, Issue 2, 2006, Pages 291-295

  Nóvoa, Sonia Rodríguez ^a   Barreiro, Pablo ^a   Rendón, Ana ^a   Barrios, Ana ^a   Corral, Angélica ^a   Jiménez Nacher, Inmaculada ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BILIRUBIN; CD4 ANTIGEN; GENOMIC DNA; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; GENES, MDR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; HYPERBILIRUBINEMIA; MALE; MIDDLE AGED; ODDS RATIO; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PYRIDINES; RISK FACTORS; RNA, VIRAL; VIRAL LOAD;

EID: 30144438738     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499056     Document Type: Article

References (27)

1. Ambudkar S, Dey S, Hrycyna C, Ramachandra M, Pastan I, Gottesman M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-98.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
3. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody MRP16. Cancer Res 1988; 48:1926-9.
4. Kim R, Fromm M, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-94.
5. Choo E, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28:655-60.
6. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57:1147-52.
7. Schinkel A, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94:4028-33.
8. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-8.
9. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-19.
10. Gerloff T, Schaefer M, Johne A, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54:610-6.
11. Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19:1581-5.
12. Fellay J, Marzolini C, Meaden E, et al. Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistant transporter 1: a pharmacogenetic study. Lancet 2002; 359:30-6.
13. Saitoh A, Singh K, Powell C, et al. An MDRJ-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 2005; 19:371-80.
14. Taburet A, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob Agents Chemother 2004; 48:2091-6.
15. Tribut O, Arvieux C, Michelet C, Chapplain J, Allain H, Bentue-Ferrer D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit 2002; 24:554-62.
16. Barrios A, Rendón A, Gallego O, Soriano V. Predictors of virological response to atazanavir in protease inhibitors experienced patients. HIV Clin Trials 2004; 5:201-5.
17. Nauck M, Stein U, von Karger S, Marz W, Wieland H. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000; 46:1995-7.
18. Marzolini C, Paus E, Buclin T, Kim R. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
19. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72:584-94.
20. Min D, Ellingrod V. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2002; 24:400-4.
21. Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation C3435T at exon 26 of the MDR1 gene on the expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71:297-303.
22. Hitzl M, Drescher S, van der Kuip H, et al. The C3435 mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-8.
23. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53:526-34.
24. Fletcher C, Jiang H, Brundage R, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359. J Infect Dis 2004; 189:1176-84.
25. Klein C, Bertz R, Ashbrenner E, et al. Assessment of the multiple dose PK interaction of LPV/RTV with NFV [abstract 536]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003:247.
26. Barreiro P, Rendón A, Rodríguez-Nóvoa S, Soriano V. Atazanavir: the advent of a new generation of more convenient protease inhibitors. HIV Clin Trials 2005; 6:50-61.
27. O'Mara E, Randall D, Passarell J, Steinberg S, Grasela D. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate- glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects [abstract A-1253]. In: Program and abstracts of the 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:11.